GSK is quietly building a new treatment pipeline, in parallel to its established work on molecular medicines, that hopes to use peoples’ nerves to treat disease. If successful, it could not only revolutionize its product offering, but change the very way we think of medicine.
“There are fewer players looking at it,” said Kris Famm, who leads the dedicated R&D unit at GSK. “We’ve gone out on a limb to capture what we believe is a game-changing therapeutic opportunity.”
{iframe}http://www.forbes.com/sites/jonathansalembaskin/2015/11/16/gsk-has-the-nerve-to-innovate-medicine/{/iframe}